CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 112 enrolled
Drug / intervention
levodopa +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00096720
NCT00096720Phase 2Completed
CompareCT.gov

Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's

Institute for Neurodegenerative Disorders·interventional·Posted Nov 15, 2004·Updated Sep 29, 2010

In Brief

A Phase 2 clinical trial evaluating levodopa, Mirapex (pramipexole), and 1 other intervention for Parkinson Disease and Parkinsonian Syndrome. Completed, enrolled 112 participants across 13 sites.

Detailed Summary

Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Parkinsonian Syndrome
CountriesUnited States
CollaboratorsBoehringer Ingelheim, United States Department of Defense

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 15, 2004
Enrollment StartFeb 1, 2004
Study CompletionMay 1, 2007
TodayJul 2, 2026
Posted 21.6 years ago

Interventions

levodopadrug

Mirapex (pramipexole)drug

[123I]ß-CIT and SPECT imagingprocedure